Diagnosis and Treatment of Peptic Ulcer Disease

被引:177
|
作者
Kavitt, Robert T. [1 ]
Lipowska, Anna M. [2 ]
Anyane-Yeboa, Adjoa [1 ]
Gralnek, Ian M. [3 ,4 ]
机构
[1] Univ Chicago, Sect Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA
[2] Univ Illinois, Div Gastroenterol & Hepatol, Chicago, IL USA
[3] Emek Med Ctr, Inst Gastroenterol Hepatol & Nutr, 21 Izhak Rabin Blvd, IL-1834111 Afula, Israel
[4] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel
关键词
Helicobacter pylori; Peptic ulcer disease; HELICOBACTER-PYLORI INFECTION; UNIDENTIFIED CURVED BACILLI; PROTON PUMP INHIBITORS; DOSE ASPIRIN THERAPY; RISK-FACTORS; DOUBLE-BLIND; PREVENTION; MANAGEMENT; COMPLICATIONS; PATHOGENESIS;
D O I
10.1016/j.amjmed.2018.12.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peptic ulcer disease continues to be a source of significant morbidity and mortality worldwide. Approximately two-thirds of patients found to have peptic ulcer disease are asymptomatic. In symptomatic patients, the most common presenting symptom of peptic ulcer disease is epigastric pain, which may be associated with dyspepsia, bloating, abdominal fullness, nausea, or early satiety. Most cases of peptic ulcer disease are associated with Helicobacter pylori infection or the use of nonsteroidal anti-inflammatory drugs (NSAIDs), or both. In this review, we discuss the role of proton pump inhibitors in the management of peptic ulcer disease, highlight the latest guidelines about the diagnosis and management of H. pylori, and discuss the latest evidence in the management of complications related to peptic ulcer disease, including endoscopic intervention for peptic ulcer-related bleeding. Timely diagnosis and treatment of peptic ulcer disease and its sequelae are crucial in order to minimize associated morbidity and mortality, as is prevention of peptic ulcer disease among patients at high risk, including those infected with H. pylori and users of NSAIDs. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:447 / 456
页数:10
相关论文
共 50 条
  • [41] Emerging Trends and their Impacts on Peptic Ulcer Diseases: Treatments and Techniques
    Singh, Pranjal Kumar
    Easwari, T. S.
    CURRENT DRUG THERAPY, 2022, 17 (01) : 2 - 11
  • [42] Pediatric gastritis and peptic ulcer disease
    Blecker U.
    Mehta D.I.
    Gold B.D.
    The Indian Journal of Pediatrics, 1999, 66 (5) : 725 - 733
  • [43] Medical treatment of peptic ulcer disease: Where do we stand?
    Sbeih, F
    SAUDI MEDICAL JOURNAL, 1998, 19 (05) : 542 - 545
  • [44] CYTOKINES AND PEPTIC-ULCER DISEASE
    MULLER, MJ
    HUNT, RH
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1993, 5 : S69 - S73
  • [45] Helicobacter pylori and peptic ulcer disease
    vanderHulst, RWM
    Tytgat, GNJ
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1996, 31 : 10 - 18
  • [46] Helicobacter pylori and peptic ulcer disease
    Blum, AL
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1996, 31 : 24 - 27
  • [47] Gastritis and peptic ulcer disease in childhood
    U. Blecker
    B. D. Gold
    European Journal of Pediatrics, 1999, 158 : 541 - 546
  • [48] Gastritis and peptic ulcer disease in childhood
    Blecker, U
    Gold, BD
    EUROPEAN JOURNAL OF PEDIATRICS, 1999, 158 (07) : 541 - 546
  • [49] Surgical management of peptic ulcer disease
    Wang, Alice
    Yerxa, John
    Agarwal, Suresh
    Turner, Megan C.
    Schroder, Vanessa
    Youngwirth, Linda M.
    Lagoo-Deenadayalan, Sandhya
    Pappas, Theodore N.
    CURRENT PROBLEMS IN SURGERY, 2020, 57 (02)
  • [50] New Molecular Targets for Treatment of Peptic Ulcer Disease
    Frank S. Lehmann
    Pius Hildebrand
    Christoph Beglinger
    Drugs, 2003, 63 : 1785 - 1797